The rhino population in Africa is at an all-time low, with more than 4,000 in South Africa alone.
As of December, there are only 738,000 rhinos in Africa.
But that doesn’t mean that there aren’t many potential rhino candidates for breeding.
A new study in the Journal of Mammalogy found that the rhino genome has the potential to be an effective breeding tool for scientists to study and breed.
The researchers from the University of California, Berkeley and the Max Planck Institute for Ornithology in Germany found that there are enough genetic variants to identify more than 50 different breeding lines that could help scientists better understand the genetic diversity of rhinos.
Rhinos are one of the largest and most threatened mammals in the world.
As recently as 2001, the African rhino was considered the most endangered mammal on the planet.
It’s not clear whether there are any rhinos left in Africa that could be successfully bred, but the study does offer some hope for the species.
Rhinoceros horns are used in traditional medicine and as food for the animals in traditional Chinese medicine.
It also has a reputation as a potent aphrodisiac, as it can be used to treat malaria and other ailments.
A recent report in the journal Molecular Biology and Evolution suggests that rhinoceroses may have a special ability to make the drug amitriptyline more effective.
This ability has been shown in animals that are genetically engineered to produce a molecule that mimics the amitrite, which can be synthesized from natural compounds.
The team of researchers discovered that a protein called TnR was able to mimic this chemical in a rhino strain.
The group used TnRs gene to identify genes in the genome that had the ability to modify the aminopeptidase enzyme, which converts amitroporphyrin (AP) into the drug.
TnRNAs also can change the expression of other genes, and the team also found that they were also able to regulate a gene called CpG dinucleotides that are used to identify the genetic variation that produces the compound.
“This discovery has the opportunity to allow us to further develop novel genetic techniques to enhance the drug’s effectiveness against malaria and malaria-related parasites,” said senior author Michael Rutter, who is a professor in the UC Berkeley Department of Molecular Biology.
“Our study shows that our research has uncovered an exciting and promising new avenue of research for identifying the genetic variations that might contribute to the effectiveness of AP-based treatment.”